Ann Intensive Care:高强度与低强度NPPV对AECOPD患者的生理影响

2022-05-31 小文子 MedSci原创

高强度NPPV在降低AECOPD患者的PaCO2、吸气费力,缓解呼吸困难,改善意识和NPPV耐受性方面是否比低强度NPPV更有效?

无创正压通气(NPPV)越来越多地应用于慢性阻塞性肺疾病急性加重期(AECOPD)患者的治疗。高强度NPPV是一种限制通气的形式,IPAP水平通常在20~30 cmH2O之间,作为一种新的通气方式被引入,通过逐步提高IPAP,最大限度降低升高的PaCO2至正常水平。然而,没有数据表明AECOPD患者应用高强度NPPV是否优于低强度NPPV。Annals of Intensive Care杂志发表的一项研究探索了高强度NPPV在降低AECOPD患者的PaCO2、吸气费力,缓解呼吸困难,改善意识和NPPV耐受性方面是否比低强度NPPV更有效。

研究人员将24例AECOPD患者随机分为高强度NPPV(n = 12)和低强度NPPV(n = 12)两组。在高强度NPPV组,最初以1~2 cmH2O的增量/减量调整IPAP,通常范围为20~30 cmH2O(或可耐受的最大值),以获得10~15mL/kg预测体重的潮气量和 < 25次/min的呼吸速率。在低强度NPPV组以及6小时筛选期间,根据患者的耐受性,IPAP最初以1~2 cmH2O(最高可达20 cmH2O)的增量/增量进行调整,以获得6~10mL/kg预测体重的潮气量和 < 25次/min的呼吸速率。

主要结局是随机分组后24小时的PaCO2。次要结局为气体交换、吸气费力、呼吸困难、意识、NPPV耐受性、人机不同步、心功能、呼吸机诱导的肺损伤和NPPV相关不良事件。

结果显示,随机分组24h后,高强度NPPV组的吸入气道正压显著升高(28.0 [26.0~28.0] vs 15.5 [15.0~17.5] cmH2O;p=0.001);随机分组24h内,高强度NPPV组的NPPV持续时间显著长于低强度NPPV组(21.8±2.1 vs 15.3±4.7h;p = 0.001)。随机分组24小时后,高强度NPPV组PaCO2降至54.0±11.6mmHg,而低强度NPPV组仅降至67.4±10.6 mmHg(p = 0.008)。高强度组呼吸-食管压力波动、食管压力-时间乘积(PTPes)/呼吸、PTPes/min、PTPes/L明显降低。随机分组后24h的副肌使用和呼吸困难评分也显著降低。两组间意识、NPPV耐受性、人机不同步、心功能、呼吸机诱导的肺损伤、NPPV相关不良事件均无差异。

结果表面,在降低AECOPD患者PaCO2升高、减少吸气费力和缓解呼吸困难方面,高强度NPPV比低强度NPPV更有效。 

 

原文出处:

Zujin Luo, Zhixin Cao,et al, Physiological effects of high-intensity versus low-intensity noninvasive positive pressure ventilation in patients with acute exacerbation of chronic obstructive pulmonary disease: a randomised controlled trial. Annals of Intensive Care, 2022, https://doi.org/10.1186/s13613-022-01018-4.    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2039321, encodeId=04e42039321f1, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Jun 26 23:48:53 CST 2022, time=2022-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488871, encodeId=464814888e151, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Wed Jun 01 13:48:53 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575034, encodeId=713715e5034c3, content=<a href='/topic/show?id=942c2045b2' target=_blank style='color:#2F92EE;'>#AECOPD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2045, encryptionId=942c2045b2, topicName=AECOPD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592616051717, createdName=fengyi817, createdTime=Wed Jun 01 13:48:53 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604058, encodeId=16e81604058d0, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Wed Jun 01 13:48:53 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223703, encodeId=574b1223e0366, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Tue May 31 20:23:20 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2039321, encodeId=04e42039321f1, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Jun 26 23:48:53 CST 2022, time=2022-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488871, encodeId=464814888e151, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Wed Jun 01 13:48:53 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575034, encodeId=713715e5034c3, content=<a href='/topic/show?id=942c2045b2' target=_blank style='color:#2F92EE;'>#AECOPD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2045, encryptionId=942c2045b2, topicName=AECOPD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592616051717, createdName=fengyi817, createdTime=Wed Jun 01 13:48:53 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604058, encodeId=16e81604058d0, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Wed Jun 01 13:48:53 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223703, encodeId=574b1223e0366, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Tue May 31 20:23:20 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
    2022-06-01 gous
  3. [GetPortalCommentsPageByObjectIdResponse(id=2039321, encodeId=04e42039321f1, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Jun 26 23:48:53 CST 2022, time=2022-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488871, encodeId=464814888e151, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Wed Jun 01 13:48:53 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575034, encodeId=713715e5034c3, content=<a href='/topic/show?id=942c2045b2' target=_blank style='color:#2F92EE;'>#AECOPD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2045, encryptionId=942c2045b2, topicName=AECOPD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592616051717, createdName=fengyi817, createdTime=Wed Jun 01 13:48:53 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604058, encodeId=16e81604058d0, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Wed Jun 01 13:48:53 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223703, encodeId=574b1223e0366, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Tue May 31 20:23:20 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
    2022-06-01 fengyi817
  4. [GetPortalCommentsPageByObjectIdResponse(id=2039321, encodeId=04e42039321f1, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Jun 26 23:48:53 CST 2022, time=2022-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488871, encodeId=464814888e151, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Wed Jun 01 13:48:53 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575034, encodeId=713715e5034c3, content=<a href='/topic/show?id=942c2045b2' target=_blank style='color:#2F92EE;'>#AECOPD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2045, encryptionId=942c2045b2, topicName=AECOPD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592616051717, createdName=fengyi817, createdTime=Wed Jun 01 13:48:53 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604058, encodeId=16e81604058d0, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Wed Jun 01 13:48:53 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223703, encodeId=574b1223e0366, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Tue May 31 20:23:20 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
    2022-06-01 aids219
  5. [GetPortalCommentsPageByObjectIdResponse(id=2039321, encodeId=04e42039321f1, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Jun 26 23:48:53 CST 2022, time=2022-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488871, encodeId=464814888e151, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Wed Jun 01 13:48:53 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575034, encodeId=713715e5034c3, content=<a href='/topic/show?id=942c2045b2' target=_blank style='color:#2F92EE;'>#AECOPD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2045, encryptionId=942c2045b2, topicName=AECOPD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=592616051717, createdName=fengyi817, createdTime=Wed Jun 01 13:48:53 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604058, encodeId=16e81604058d0, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Wed Jun 01 13:48:53 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223703, encodeId=574b1223e0366, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Tue May 31 20:23:20 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
    2022-05-31 医鸣惊人

    认真学习了

    0

相关资讯

Respir Res:我国慢阻肺严重程度分布与治疗现状

COPD患者普遍存在中重度气流受限、症状严重和病情恶化风险。维持疗法的处方并没有完全遵循指南建议。

Eur J Epidemiol:心肺健康并不能抵消吸烟导致的慢性阻塞性肺疾病风险的增加

慢性阻塞性肺疾病(COPD)是一种慢性肺部炎症性疾病,导致进行性不可逆转的气流阻塞。

Clin Microbiol Infect:铜绿假单胞菌在慢性阻塞性肺疾病患者中的持久性和遗传适应性

铜绿假单胞菌是慢性阻塞性肺疾病(COPD)患者细菌感染的常见原因,可从4%-15%的成人COPD患者的痰标本中分离到铜绿假单胞菌。

NPJ Vaccines:疫苗株对慢性阻塞性肺疾病患者和健康老年人流感疫苗免疫后血清阳转率的影响

慢性阻塞性肺疾病(COPD)是一种常见的、严重的肺部疾病,由吸烟和暴露在空气污染物中引起。

Mayo Clin Proc:成人慢性阻塞性肺疾病心肌梗死后心脏选择性与非选择性β受体阻滞剂的比较

慢性阻塞性肺疾病(COPD)的特点是进行性气流受限,并与肺部的异常炎症反应有关。此外,COPD是一种高度全身性炎症状态,可能导致动脉粥样硬化、斑块破裂和血栓形成。

OMCL:慢性阻塞性肺疾病患者S100A4、鞘氨醇-1-磷酸与肺功能的关系

慢性阻塞性肺疾病(COPD)以不可逆性气流受限和慢性气道炎症为特征,给整个社会和个人带来沉重的负担。